Dr. Matthew Strobeck‘s Birchview Capital has recently disclosed its equity holdings in a 13F filing with the SEC. The market value of the fund’s equity portfolio stood at $191.76 million at the end of the March quarter with a comparatively low turnover ratio of 12.82%.
Dr. Matthew Strobeck received his doctorate degree from the University of Cincinnati in 2001. He founded the Biosciences-focused fund, Birchview Capital in 2014 and is currently its Chief Investment Officer & Limited Partner. Birchview invests primarily in healthcare and environment industries. Strobeck is also an Independent Director at Accelerate Diagnostics Inc (NASDAQ:AXDX), and Metabolix, Inc. (NASDAQ:MBLX). Previously, he was a Partner at Westfield Capital Management and also served as a consultant for Thomas Weisel Asset Management. Some of the top picks of the fund at the end of the first quarter were Celgene Corporation (NASDAQ:CELG), Vermillion, Inc. (NASDAQ:VRML), and EQT Corporation (NYSE:EQT).
Through our research at Insider Monkey, we have formulated a portfolio strategy based on 15 most popular small cap picks of hedge funds. Back tests ranging from 1991 to 2012 revealed that this strategy outperformed the market by nearly a percentage point per month, while the most popular large cap picks of hedge funds underperformed the market by 7 basis points per month during the same period. In forward tests since August 2012 through March 2015 our small cap strategy beat the market by a hefty 79.4 percentage points (read the details here). Hence a retail investor needs to isolate himself from the herd and take advantage of the prevalent arbitrage opportunities in the market by concentrating on small-caps
Birchview added 26,252 shares of Celgene Corporation (NASDAQ:CELG) in the first quarter to take the company’s holding to 840,163 shares valued at $96.86 million. The holding is by far the fund’s largest and amasses 50.51% of the fund’s portfolio value. Among the billionaires that we track, five had an aggregate investment of $201.81 million in Celgene Corporation (NASDAQ:CELG) at the end of the fourth quarter. Ken Griffin was one of them as his fund, Citadel Investment Group, held about 924,600 shares valued at $103.43 million.